Gapping up
In reaction to earnings/guidance:
- WGO +6.1%, APOG +2.7%
M&A news:
- BEAT +17% (BioTelemetry to be acquired by Philips (PHG) for $72.00 per share), PHG +1.7%
Other news:
- MREO +38.9% (MREO and RARE announce collaboration and license agreement for setrusumab)
- DMTK +25.7% (announces positive results of TRUST Study)
- TLC +6.2% (provides study updates at investor conference; Patient enrollment of EXCELLENCE pivotal trial reaches 98%)
- ACTG +4.5% (President/CIO disclosed the purchase of 100K shares worth ~$377K (transaction dates 12/15-12/16) )
- VIR +4.4% (VIR and GSK start of trial evaluating VIR-7831 in hospitalized adults with COVID-19)
- MNKD +3.5% (announces co-promotion agreement for Thyquidity)
- DD +3% (approved the separation of DuPont's Nutrition & Biosciences business through an exchange offer)
- NVO +1.9% (files MMA with EMA for approval of once-weekly semaglutide)
- BCLI +1.7% (completed in the ongoing Phase 2 trial evaluating NurOwn as a treatment for progressive MS; Topline clinical trial results expected by the end of the first quarter 2021)
- POR +1.3% (announced the Special Committee of the Board of Directors concluded its independent review of the energy trading activity that led to the losses incurred in the third quarter)
- AR +1.2% (S&P outlook revised to stable from negative)
- EGBN +1% (announces new share repurchase program)
- TME +1% (Tencent Music consortium exercises call option to acquire additional equity interests in Universal Music Group)
Analyst comments:
- MYE +4.4% (upgraded to Overweight from Sector Weight at KeyBanc Capital Markets)
- ABNB +3.6% (initiated with a Positive at Susquehanna)
- DOW +2% (upgraded to Overweight from Neutral at JP Morgan)
- NRZ +1.6% (upgraded to Outperform from Mkt Perform at Keefe Bruyette)
- NLY +1% (upgraded to Outperform from Mkt Perform at Keefe Bruyette)